As of June 13, 2014
These are the preliminary additions and deletions for the Russell Global, Russell 3000® and Russell Microcap® Indexes.
Nanosphere made the boot list. They're getting deleted from Russell 3000 unless there is a sudden sharp share price increase.
Preliminary additions and deletions to the Russell Global, Russell 3000® and Russell Microcap® Indexes published after 3:00 p.m. PST
Updates to the list of additions and deletions
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
Good point on the Russell 3000 rebalance. Last year the smallest company included had a $129 mil market cap. NSPH is likely to get booted and that could explain some of the selling but I think your $.50 target is unrealistic.
Do the math.
From their latest 10Q.
"We do not anticipate achieving positive operating cash flow in at least the next twelve months."
'We expect to increase investment in additional manufacturing scale-up, and to add sales, marketing and customer support personnel during the next twelve months."
and "As of March 31, 2014, we had $33.0 million in cash and cash equivalents as compared to $41.5 million at December 31, 2013, a decrease of $8.5 million."
At the current cash burn they'll need to raise more cash.
at any of the recent shows? This thing is trading like someone knows it's coming.
Put a dollar figure on Tiny's investment in D Wave and I'll try real hard to care.
November 11, 2013
Lockheed Martin Open Discussion on D-Wave
Shareholders of Harris & Harris Group, Inc., may be interested to join a dialogue with Lockheed Martin scientists on their engagement with Harris & Harris Group portfolio company D-Wave. The event can be accessed at (check on TINY website under investor relations for link)
Harris & Harris Group is an investor in privately-held D-Wave.
From their 10Q filed May 10, 2013
"During the three months ended March 31, 2013, we sold the remaining 50,807 shares of our position in NeoPhotonics Corporation. We no longer own any shares of NeoPhotonics. For the three months ended March 31, 2013, we received $252,042 in proceeds, net of commission, from the sale of NeoPhotonics shares. We also received proceeds of $24,146 from call option premiums on shares of NeoPhotonics. Since its IPO, the sale of our 450,907 shares of NeoPhotonics generated net proceeds of $2,239,809, or an average sale price, net of commission, of $4.97 per share. Including premiums from call options, the average sale price for these shares was $5.45 per share. Our cost basis in NeoPhotonics was $16.19 per share."
AVEO Pharma (AVEO) Recieves Subpoena From SEC on Tivozanib
Street Insider - 4:37 PM ET
On July 3, 3013, AVEO Pharmaceuticals, Inc. received a subpoena from the United States Securities and Exchange Commission requesting documents and information concerning tivozanib, which the U.S. Food and Drug Administration declined to approve for the treatment of patients with advanced renal cell carcinoma on June 10, 2013, including related communications with the FDA, investors and others.
Tedizolid Achieves All FDA and EMA Endpoints in First Phase 3 Trial Conducted Under New Draft Guidance for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
SAN DIEGO, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious infections, announced today that the results from ESTABLISH 1, a Phase 3 study of tedizolid phosphate (TR-701) versus linezolid (Zyvox(R)) completed in 2011, have been published in The Journal of the American Medical Association (JAMA).
The ESTABLISH 1 trial examined the efficacy and safety of a 200 mg tablet of tedizolid given once a day for six days versus a 600 mg tablet of linezolid given twice a day for 10 days in 667 patients in North America, Latin America and Europe. The trial was the first pivotal study conducted to prospectively measure the new FDA "early response" primary endpoint of cessation of lesion spread and absence of fever 48-72 hours after the first dose. The trial also measured as secondary endpoints this "early response" sustained to the end of therapy (EOT; day 11) as well as captured the EMA endpoint of clinical investigator's assessment at the post-treatment evaluation visit (7-14 days after EOT).
As detailed in the JAMA article, tedizolid achieved the primary and all secondary endpoints in the ESTABLISH 1 trial. Approximately 42 percent of pathogens isolated at baseline in the study were methicillin resistant Staphylococcus aureus (MRSA). For both tedizolid and linezolid there was good concordance ( 80%) between the early primary endpoint and late investigator assessed secondary endpoints suggesting that the early response is a good indicator of a sustained clinical response to therapy. In addition, the trial showed that tedizolid had a statistically lower impact on platelets and was associated with a statistically significant lower rate of gastrointestinal (GI) adverse events than linezolid.
"While being the pioneer on a pivotal study conducted under new guidance offers many challenges, the results speak for themselves and are a testimony to the extraordinary efforts of the Trius team working in concert with the FDA," said Philippe Prokocimer, M.D., Chief Medical Officer at Trius and lead author of the JAMA article. "Publication of the ESTABLISH 1 trial results in JAMA further confirms the need for new antibiotics such as tedizolid."
In an accompanying editorial in the JAMA issue, Drs. Shira Doron and Helen Boucher state, "Much can be learned from the current study about the appropriate use of antibiotics for the treatment of these common infections, and the design of future trials for treatment of ABSSSI." They also highlight that "Tedizolid is a new oral antibiotic that appears efficacious using a short course of therapy and may have a better safety profile than linezolid."
In December 2012, Trius announced that it completed enrollment of its second ABSSSI trial, ESTABLISH 2. This second pivotal Phase 3 trial was designed to evaluate the efficacy and safety of tedizolid and linezolid when initially administered as an intravenous (IV) infusion with the option to switch to oral therapy. Trius expects to report top-line results from the ESTABLISH 2 study around the end of the first quarter of this year.
Array Biopharma (ARRY) Files $200M Mixed Shelf
7:09 AM ET, 12/21/2012 - Street Insider
Array Biopharma, Inc. (NASDAQ: ARRY) filed a registration with the U.S. SEC to sell, from time to time, up to $200 million of Common Stock, Preferred Stock, Depositary Shares, Debt Securities, Warrants, Units, or any combination thereof.
the credit goes the Adam Feuerstein . he tweeted this info today ... @adamfeuerstein
Diamondback owned 2.3M shares of $YMI as of last 13F. Only biotech stock that stood out to me, rest fairly liquid names.
Bloomberg story ..."Diamondback to Close Down as Investors Pull $520 Million"
"Diamondback Capital Management LLC, among the hedge funds raided by the FBI two years ago in the U.S. investigation of insider trading on Wall Street, is liquidating after an exodus of clients."
as of 09/30/2012 filings Diamondback Capital Management LLC owned 2.2 million shares of YMI.
"The fund received requests from investors to withdraw about $520 million, or 26 percent of its assets, co-founders Richard Schimel and Lawrence Sapanski said today in a client letter. The Stamford, Connecticut-based firm, which has 133 employees, plans to return the majority of clients’ cash next month."
maybe they already sold their remaining shares in YMI?
$CELG $CELGZ Abraxane ph 3 pancreatic cancer trial hits stat sig improvement in overall survival
HANGZHOU, ZHEJIANG PROVINCE, CHINA & NEW YORK — Pfizer Inc. (NYSE: PFE), the world’s largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals (SSE Code: 600267), a leading Chinese pharmaceutical company, today announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd. (hereafter referred to as Hisun-Pfizer), a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets. The creation of the joint venture marks an important milestone in strengthening the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena.
A J-V and a merger are two different animals. Still might be worth a hmmmm but the off-patent part doesn't fit.